射波刀治疗原发性肝癌328例初步结果分析

Outcome of patients with primary liver cancer treated by cyberknife:A retrospective review of 328 cases

目的:初步探讨射波刀在原发性肝癌治疗中的效果及并发症。方法:选择2007年12月至2012年12月收治的原发性肝癌328例,其中男性288例,女性40例,年龄21~79岁,平均52.5岁。采用射波刀治疗,分割1~10次,平均4.35次,照射剂量24.5~52Gy,平均42.7Gy,剂量曲线从56%~90%,平均69.3%。结果:随访6个月至74个月,平均22个月。按照mRECIST标准,治疗后6个月复查CT/MR,局部完全缓解(CR)29例(8.8%)、部分缓解(PR)201例(61.3%)、稳定(SD)63例(19.2%)、进展(PD)35例(10.7%),中位无进展生存14.38个月,总生存17.3个月。结论:射波刀治疗原发性肝癌是一种有效和安全的治疗模式。

Objective: To investigate the outcomes and complications of cyberknife in patients with primary liver cancer. Methods: Data of 328 patients with primary liver cancer treated by cyberknife was analyzed,including 288 males and 40 females. The age of patients ranged from 21 to 79 years old,with average age 52. 5 years old. The radiotherapy fractions were 1 ~ 10( average 4. 35). The total dose was 24. 5 ~ 52Gy( average 42. 7Gy). Isodose curve was from 56% ~ 90%( average 69. 3%). Results: The follow- up time was from 6 months to 74 months( average 22months). According to mRECIST standard,CT / MR were reviewed after 6 months of treatment,with complete remission( CR) in 2 9 cases( 8. 8%),partial remission( PR) in 201 cases( 61. 3%),stable disease( SD) in 63 cases( 19. 2%),progress disease( PD) in 35 cases( 10. 7%). Median progression free survival was 14. 38 months,the median overall survival 17. 3 months. Conclusion: Cyberknife is an effective and safe treatment of primary liver cancer.